Study of glumetinib plus nab-docetaxel for advanced stomach cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs, glumetinib and nab-docetaxel, in people with advanced stomach cancer or other solid tumors that have a specific change in the MET gene. The goal is to see if this combination is safe and works better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced stomach cancer or another solid tumor that has spread.
- Your tumor must have a change in the MET gene (overexpression or amplification) confirmed by a central lab.
- You cannot have received prior treatment with a MET-targeted drug or docetaxel.
- You must be in fairly good health (ECOG score 0 or 1) and expected to live at least 3 more months.
- You cannot have untreated or worsening brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of two medicines for people with advanced non-small cell lung cancer that has a specific marker called MET overexpression. The trial hopes to see if adding the new drug (glumetinib) to standard chemotherapy works better than chemotherapy alone.
This trial is testing a new form of the chemotherapy drug docetaxel (called albumin-bound docetaxel) for people with advanced stomach or gastroesophageal junction cancer that has worsened after initial treatment. It aims to see if this version of the drug works better or has fewer side effects.
This trial tests a new drug combination for people with advanced stomach or gastroesophageal junction cancer that has grown after earlier treatment. It aims to see if adding these drugs can help shrink tumors or slow the disease.
This trial tests a new combination of two targeted drugs, glumetinib and osimertinib, for people with advanced non-small cell lung cancer (NSCLC). The goal is to see if the combination can help control the cancer better than standard treatments.
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
This trial tests a combination of two drugs—nab-paclitaxel (a chemotherapy drug) and cadonilimab (an immunotherapy drug)—for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this combination can help shrink or control the cancer when other treatments haven't been tried yet.
Hear when a new Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.